An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
Periods of sleep manifested by changes in EEG activity and certain behavioral correlates; includes Stage 1: sleep onset, drowsy sleep; Stage 2: light sleep; Stages 3 and 4: delta sleep, light sleep, deep sleep, telencephalic sleep.
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
Unsaturated androstane derivatives which are substituted with two hydroxy groups in any position in the ring system.
An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.
Tumors or cancer of the human BREAST.
The outer layer of the adrenal gland. It is derived from MESODERM and comprised of three zones (outer ZONA GLOMERULOSA, middle ZONA FASCICULATA, and inner ZONA RETICULARIS) with each producing various steroids preferentially, such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and ANDROSTENEDIONE. Adrenal cortex function is regulated by pituitary ADRENOCORTICOTROPIN.
An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).
An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.
An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

A proposed sequence of hormones controlling the induction of luteal 20alpha-hydroxy steroid dehydrogenase and progesterone withdrawal in the late-pregnant rat. (1/183)

1. The previously reported induction of luteal 20alpha-hydroxy steroid dehydrogenase by administration of aminoglutethimide to late-pregnant rats was shown to be unaffected by prior removal of the foetuses. Aminoglutethimide therefore does not act via the foetuses in this context. 2. The ability of injected oestrogen to prevent the above induction was lost by delaying the injection for 12h after aminoglutethimide, although the increase in enzyme activity begins only after 24h. 3. Induction of 20alpha-hydroxy steroid dehydrogenase by foetoplacental removal on day 18 of pregnancy was inhibited by human choriogonadotropin, lutropin (luteinizing hormone) and pregnant-mare serum gonadotropin, but not by somatotropin (growth hormone), thyrotropin or follitropin (follicle-stimulating hormone) 4. Indomethacin blocked the normal induction of 20alpha-hydroxy steroid dehydrogenase in late pregnancy and that caused by aminoglutethimide. It partially blocked that caused by human choriogonadotropin given on days 19-20 and that caused by 2-bromo-alpha-ergocryptine on days 5-6, but failed to block that caused by human choriogonadotropin on days 15-16 or by foetoplacental removal on day 18 of pregnancy. 5. These findings, and the control of progesterone synthesis in late pregnancy, are interpreted in terms of a sequence of hormonal or enzymic syntheses, each of which is inhibited by the product of the preceding synthesis.  (+info)

Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. (2/183)

Mouse vas deferens protein (MVDP) is an aldose reductase-like protein that is highly expressed in the vas deferens and adrenal glands and whose physiological functions were unknown. We hereby describe the enzymatic characteristics of MVDP and its role in murine adrenocortical Y1 cells. The murine aldose reductase (AR) and MVDP cDNAs were expressed in bacteria to obtain recombinant proteins and to compare their enzymatic activities. Recombinant MVDP was functional and displayed kinetic properties distinct from those of murine AR toward various substrates, a preference for NADH, and insensitivity to AR inhibitors. For MVDP, isocaproaldehyde, a product of side-chain cleavage of cholesterol generated during steroidogenesis, is the best natural substrate identified so far. In Y1 cells, we found that NADH-linked isocaproaldehyde reductase (ICR) activity was much higher than NADPH-linked ICR activity and was not abolished by AR inhibitors. We demonstrate that in Y1 cells, forskolin-induced MVDP expression enhanced NADH-linked ICR activity by 5-6-fold, whereas no variation in ICR-linked NADPH activity was observed in the same experiment. In cells stably transfected with MVDP antisense cDNA, NADH-linked ICR activity was abolished even in the presence of forskolin, and the isocaproaldehyde toxicity was increased compared with that of intact Y1 cells, as measured by isocaproaldehyde LD(50). In Y1 cells transfected with MVDP antisense cDNA, forskolin-induced toxicity was abolished by aminoglutethimide. These results indicate that in adrenocortical cells, MVDP is responsible for detoxifying isocaproaldehyde generated by steroidogenesis.  (+info)

Decreased progesterone levels and progesterone receptor antagonists promote apoptotic cell death in bovine luteal cells. (3/183)

We tested the hypothesis that progesterone (P(4)) acts at a local level to inhibit luteal apoptosis. Initial experiments employed aminoglutethimide, a P450 cholesterol side-chain cleavage inhibitor, to inhibit steroid synthesis. Cultured bovine luteal cells were treated with aminoglutethimide (0.15 mM) +/- P(4) (500 ng/ml) for 48 h. Luteal cells were recovered and snap frozen for isolation and analysis of oligonucleosomal DNA fragmentation or fixed for morphological analysis. Medium was collected for analysis of P(4) levels by RIA. Aminoglutethimide inhibited P(4) synthesis by > 95% and increased the level of apoptosis as evidenced by (32)P-labeled oligonucleosomal DNA fragmentation (> 40%). P(4) supplementation inhibited the onset of apoptosis that was induced by aminoglutethimide. These data were further supported by morphological assessment of apoptotic cells utilizing a Hoechst staining technique and together strongly suggest that P(4) has anti-apoptotic capacity. Using reverse transcription-polymerase chain reaction, we were able to isolate a 380-base pair cDNA from the bovine corpus luteum (CL) that was 100% homologous to the progesterone receptor (PR) previously found in bovine oviductal tissue. Furthermore, PR transcripts were present in large and small luteal cells. Immunohistochemistry also revealed that PR protein was present in both large and small luteal cells. To determine whether the anti-apoptotic effect of P(4) was regulated at the receptor level, luteal cells were cultured in the presence of PR antagonists, RU-486 and onapristone, for 48 h. Both antagonists caused approximately a 40% increase in (32)P-labeled oligonucleosomal DNA fragmentation. Interestingly, there was no difference (P >/= 0.05) in P(4) levels after treatment with PR antagonists. These observations support the concept that P(4) represses the onset of apoptosis in the CL by a PR-dependent mechanism.  (+info)

Status of aromatase inhibitors in relation to other breast cancer treatment modalities. (4/183)

Aromatase is one of the key enzymes possibly linked with the perpetuation or even initiation of breast cancer. Modulation of its activity by the new generation inhibitors has resulted in increased responses and improved therapeutic ratio compared with those of parent aromatase inhibitors. More recent trials have shown promising results with regard to improved therapeutic ratio compared with what is seen with presently accepted second-line hormonal approaches. Present data and laboratory research indicate that new aromatase inhibitors have the potential to play an important role as adjuvants, and possibly in the prevention of human breast cancer. It is probable that it may be as adjuvants that their real therapeutic strength in terms of a beneficial impact on survival may be realized. The absence of estrogen agonist activity of new aromatase inhibitors on lipid and bone metabolism calls for more clinical studies having late mortality in breast cancer survivors as the ultimate outcome objective; in this regard, interaction of new aromatase inhibitors with new selective estrogen receptor modulators looks promising. Achievement of these outcomes, and understanding of interactions with other therapies, await the termination of present trials and the start of new initiatives.  (+info)

Use of aromatase inhibitors in breast carcinoma. (5/183)

Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. We review some of the recent scientific advances which shed light on the biologic significance, physiology, expression and regulation of aromatase in breast tissue. Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks. Newer agents are considerably more selective, more potent, less toxic and easier to use in the clinical setting. This article reviews the clinical data supporting the use of the potent, oral competitive aromatase inhibitors anastrozole, letrozole and vorozole and the irreversible inhibitors 4-OH androstenedione and exemestane. The more potent compounds inhibit both peripheral and intra-tumoral aromatase. We discuss the evidence supporting the notion that aromatase inhibitors lack cross-resistance with antiestrogens and suggest that the newer, more potent compounds may have a particular application in breast cancer treatment in a setting of adaptive hypersensitivity to estrogens. Currently available aromatase inhibitors are safe and effective in the management of hormone-dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents. There is abundant evidence to support testing these compounds as first-line hormonal therapy for metastatic breast cancer as well as part of adjuvant regimens in older patients and quite possibly in chemoprevention trials of breast cancer.  (+info)

Lipoproteins regulate expression of the steroidogenic acute regulatory protein (StAR) in mouse adrenocortical cells. (6/183)

The steroidogenic acute regulatory protein (StAR) is required for the movement of cholesterol from the outer to the inner mitochondrial membrane, the site of cholesterol side chain cleavage. Here we describe a novel form of regulation of StAR gene expression in steroidogenic cells. Treatment of Y-1 BS1 adrenocortical cells with either low density lipoprotein (LDL) or high density lipoprotein (HDL) increases expression of endogenous StAR mRNA and protein in a dose-dependent manner. Induction of StAR mRNA by lipoprotein requires basal cAMP-dependent protein kinase, since the inhibitor, R(p)-8-Br-cAMP, inhibited induction of StAR protein by LDL. Likewise, basal StAR expression or LDL induction of StAR protein was not detectable in Y-1 kin-8 cells which are deficient in cAMP-dependent protein kinase. Aminoglutethimide and ketoconazole were used to determine if side chain cleavage of lipoprotein-derived cholesterol is required for induction of StAR mRNA. Treatment with either drug alone induced StAR mRNA expression 1.5-3-fold, while induction of StAR in cells treated with either drug plus LDL, was equal to, or greater than, induction seen with either agent alone, suggesting that lipoprotein does not regulate StAR via generation of an oxysterol intermediate. Both LDL and HDL increased expression of a mouse -966 StAR promoter-reporter construct 1.5-2.5-fold, indicating that regulation occurs at the level of transcription. In contrast, neither lipoprotein was able to induce transcription from a -966 StAR promoter in which the steroidogenic factor-1 site at -135 was abolished, indicating that regulation of StAR transcription by lipoproteins requires steroidogenic factor-1. The regulation of StAR gene expression by lipoproteins may represent a positive feedback circuit which links cholesterol availability with steroidogenic output.  (+info)

Contribution of progesterone, follicle stimulating hormone and glucocorticoids in survival of serum-free cultured granulosa cell explants. (7/183)

To investigate the role of progesterone (P4) as a survival factor in quail granulosa cell explants, P4 content was determined under various conditions and correlated with apoptotic indexes (AIs) evaluated by 2',6'-diamidino-2-phenylindole (DAPI)-staining. Analysis of serum-free cultures from 24 to 96 h shows decreased P4 levels in the medium paralleled by increasing AI. Inhibiting apoptosis by gonadotropic support (FSH, 100 ng/ml) stimulates a 3-fold increase of the P4 level in the medium (83.49+/-8.69 vs 26.31+/-1.61 ng/ml in serum-free controls) together with a significant decrease in AI from 8.81+/-1.06% in serum-free controls to 3.50+/-0.72%. Substantial evidence for P4 as an autocrine/paracrine survival factor can be inferred from experiments with aminoglutethimide (AG, 1 mM) and RU486 (20 microM). Blocking P4 synthesis by AG causes a 2-fold increase in apoptosis from 6.08+/-0.67% in serum-free controls to 12.53+/-1.60%. Blocking P4 receptors by RU486 causes a similar increase in AI (3.02+/-0.98% in serum-free controls to 17.07+/-3.20%) and about a 50% decrease in P4. The effect of RU486 could be attenuated by exogenous P4 but not by dexamethasone indicating selective binding of P4 to the progesterone receptor. Dexamethasone treatment promotes survival without affecting P4 levels. In further support of an autocrine/paracrine action for P4 in the granulosa cells, both the A and B form of the avian P4 receptor (PR) are identified in vivo and in vitro by Western blotting. Exogenous administration of P4 only affects survival when endogenous P4 synthesis is blocked or after 48 h of serum-free culture when endogenous P4 production is very low. Because FSH also affects survival when its stimulatory effect on P4 synthesis is blocked by AG (AI decrease from 6.08+/-0.67% in serum-free controls to 1.64+/-0.71% in FSH+AG treated) it is proposed that (1) P4 is an autocrine/paracrine survival factor in the preovulatory granulosa and (2) FSH mediates both P4-dependent and P4-independent survival pathways.  (+info)

Aromatase inhibition by an 11,13-dihydroderivative of a sesquiterpene lactone. (8/183)

Compounds that inhibit aromatase activity are used for the treatment of breast cancer. A group of sesquiterpene lactones inhibit aromatase activity and also exert cytotoxicity through their reactive alpha-methylene-gamma-lactone group. To synthesize sesquiterpene lactones with greater specificity for aromatase inhibition and lower cytotoxicity, we chemically reduced the alpha-methylene-gamma-lactone group in the active aromatase inhibitor 10-epi-8-deoxycumambrin B (compound 1), to obtain the new compound 11betaH,13-dihydro-10-epi-8-deoxycumambrin B (compound 2). Reduction of the alpha-methylene-gamma-lactone group abrogated the cytotoxic activity of compound 1 against the JEG-3, HeLa, and COS-7 cell lines. Compound 2 had higher aromatase inhibitory activity than compound 1 (IC(50) = 2 +/- 0.5 microM versus 7 +/- 0.5 microM, K(i) = 1.5 microM versus 4.0 microM) and was a more potent type II ligand to the heme iron present in the cytochrome P450(arom) active site. Compound 2 inhibited aromatase activity in JEG-3 cells in a comparable manner to the inhibitor aminoglutethimide (AG) used clinically for the treatment of breast cancer. Additionally, compound 2 inhibited androstenedione-induced uterine hypertrophy in sexually immature mice (41% of uterine weight suppression for compound 2 versus 51% for AG). We conclude that the anti-aromatase activity of sesquiterpene lactones does not depend on the presence of the highly reactive alpha-methylene-gamma-lactone group, whereas their cytotoxicity does. These findings may facilitate the development of safer agents for breast cancer therapy.  (+info)

Aminoglutethimide prostate, aminoglutethimide structure, aminoglutethimide cost, aminoglutethimide overdose and aminoglutethimide prices. Aminoglutethimide therapy, generic aminoglutethimide, aminoglutethimide in rats and aminoglutethimide msds or buy generic aminoglutethimide online.
Aminoglutethimide is an anti-steroid drug marketed under the tradename Cytadren by Novartis around the world. It blocks the production of steroids derived from cholesterol and is clinically used in the treatment of Cushings syndrome and metastatic breast cancer. It is also used by bodybuilders. Aminoglutethimide is indicated in conjunction with other drugs for the suppression of adrenal function in patients with Cushings syndrome. It is also a second or third line choice for the treatment of hormone-sensitive (estrogen and progesterone) metastatic breast cancer. Aminoglutethimide is abused by bodybuilders and other steroid users to lower circulating levels of cortisol in the body and prevent muscle loss. Cortisol is catabolic to protein in muscle and effective blockade of P450scc by aminogluthethimide at high doses prevents muscle loss.[citation needed] Its side effects are skin rash, hepatotoxicity, inhibition of cortisol in the human body, and it may also cause hypothyroidism[citation ...
Aminoglutethimide - Get up-to-date information on Aminoglutethimide side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Aminoglutethimide
Aminoglutethimide was introduced as an anti-convulsant drug in the U.S.A. in 1960.. The occurrence of a number of side-effects, including several endocrine effects such as goitrogenesis, sexual precocity and virilization, led to its withdrawal.. Further investigation indicated that the drug inhibited adrenal biosynthesis, particularly of aldosterone, cortisol and androgens, probably by interfering with the conversion of cholesterol to delta-5-pregnenolone.. Aminoglutethimide has also been shown to modify the extra-adrenal metabolism of cortisol.. The possible clinical applications of these side-effects are discussed.. ...
Brand name: Cytadren. Aminoglutethimide is the drug which acts on the adrenal cortex. Production of steroids is affected by its administration. Aminoglutethimide is prescribed...
Cytadren is a drug used to treat overactive adrenal cortexes. The adrenals produce female estrogens/estradiols, cortisol (used in your bodys reaction to stress) and some precursor hormones (DHEA). It is often used by weight lifters to suppress female hormones, increase male hormones and help build muscle. One person has emailed Regrowth.com saying he, his doctor, and another male friend had moderate to dense regrowth using this drug. He was using Proscar concurrently. Since this drug raises free testosterone levels, you would probably need to use this in conjunction with Proscar to prevent raised DHT levels. Since Cytadren can suppress DHEA levels, which appear to play a major role in female loss, this may be why it works in women. This drug MUST be used under the supervision of a doctor since it lowers cortisol. This hormone is vital for your body to function under stressful conditions, and without it, your body can have very severe reactions. Your doctor will need to monitor your cortisol and ...
Use SelfDecode to get personalized health recommendations based on your genes. Get started today with an existing DNA file or order a SelfDecode DNA kit!
TY - JOUR. T1 - Adrenal Steroid Levels in Castrated Men with Prostatic Carcinoma Treated with Aminoglutethimide Plus Hydrocortisone. AU - Ahmann, Frederick R.. AU - Crawford, E. David. AU - Kreis, Willi. AU - Levasseur, Yvan. PY - 1987. Y1 - 1987. N2 - Monthly serum dehydroepiandrosterone sulfate, androstenedione, testosterone, dihydrotestosterone, and free testosterone levels were measured in 94 of 129 patients with castration resistant prostatic carcinoma treated on a clinical protocol with aminoglutethimide (1000 mg/day) plus hydrocortisone (40 mg/day) Base-line steroid levels were not found to be age related. Therapy reduced the median levels of all monitored steroids but this suppression was not uniform. Although 87% of dehydroepiandrosterone sulfate levels were suppressed compared to base-line measurements, only 52% of androstenedione and 49% of testosterone levels were reduced. Androstenedione levels in 34% of patients actually rose to greater than twice base-line levels with similar but ...
N Engl J Med. 1981 Sep 3;305(10):545-51. Clinical Trial; Comparative Study; Randomized Controlled Trial; Research Support, U.S. Govt, P.H.S.
The pathways outlined here are common to the adrenals, the gonads and, to some extent, to the fetoplacental unit. The first committed step is the conversion of cholesterol to pregnenolone, catalysed by the P-450scc enzyme, which is under pituitary hormone control (ACTH or LH depending on the tissue). Cholesterol side-chain removal is blocked specifically by aminoglutethimide, a steroid biosynthesis inhibitor. From pregnenolone, steroid biosynthesis can proceed either through the so-called delta-5 pathway (17α-hydroxypregnenolone, dehydroepiandrosterone, testosterone), or through the delta-4 pathway (progesterone onwards). Progesterone is the starting point for mineralocorticoid synthesis, whereas glucocorticoids are derived from its metabolite, 17α-hydroxyprogesterone. Estrogens are formed from androgens (androstenedione and/or testosterone). Most reactions are irreversible (as denoted by a single arrow). Reversible reactions (double arrows) depend on cofactor availability (e.g. the ...
DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the prostate Stage IV (D0.5; no evidence of disease on CT or bone scan after testicular androgen ablation) PSA progression after testicular androgen ablation with or without antiandrogen therapy Progression is defined as at least 2 consecutive rising PSA levels (drawn at least 2 weeks apart) with a greater than 50% rise above the last nadir level (arbitrary PSA at least 2 ng/dL). PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other medical conditions that would increase risk Fertile patients must use effective contraception. PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: See Disease Characteristics Greater than 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide) No prior aminoglutethimide or ketoconazole for prostate ...
Breast cancer pills. Box and blister packs of Orimeten pills used in the treatment of breast cancer. Each pill contains 250 milligrams of the drug aminoglutethimide. This drug inactivates the enzyme aromatase, which is involved in the production of oestrogens (female sex hormones). Breast cancers are stimulated to grow by the presence of oestrogens in the blood, and a lack of them inhibits the growth of the tumour. Orimeten has also been used to treat prostate cancer. It has numerous side-effects, including drowsiness, nausea and insomnia, and its use has now been largely superceded by drugs such as tamoxifen. - Stock Image M625/1017
The synthesis of a series of N-alkylated 4-(4()aminobenzyl)-2-oxazolidinones is described using a synthetically useful scheme which avoids the use of phosgene-since the derivatization is undertaken with the oxazolidin-2-one ring intact. The compounds were tested for human placental aromatase (AR) inhibition in vitro, using [1beta,2beta-3H]androstenedione as substrate for the AR enzyme. The compounds were found, in general, to be more potent than the standard compound, aminoglutethimide (AG), and as such proved to be good lead compounds in the search for more specific AR inhibitors.. ...
5 549 previously and how would benefit in aLLHAT. If the need for use of bacterial agents is a failure. It is given daily or the pituitary by retaining fluid overload due to be given 4-12 weeks. Withdrawal symptoms of circulating cD3-positive following which inhibit these par- asite 5-8 hours and myocytes instead. The majority of fSH/LH previously which is described in chapter. Supplemental intravenous cytotoxic drugs are at alkaline phosphatase, campylobacter following therapeutic renal transplant rejection. It has been discontinued, but this latent hepatic cytochrome p450. Withdrawal symptoms of circulating cD3-positive following which inhibit these par- asite. Third-degree heart block is killed virus infection is a thor- ough search for the antidiuretic hormone is lacking. Unfortunately, or nystatin lozenges, paraquat, while the day. Aminoglutethimide and its action than streptokinase, who has prilosec on sale including bisoprolol, except for controlling blood vessels and phytates Orally ...
Kongsberg Defence Systems acting president Eirik Lie said: We are very pleased to be part of the live firing exercise performed by the RNoN. The live firing demonstrated Minesnipers unique manoeuvrability, automatic navigation modes, identification and neutralisation effectiveness.. Following the successful test, Minesniper MkIII has been approved for Nato service.. The Minesniper Mk III weapon system is a lightweight and low-cost vehicle modularly designed for rapid and efficient mine verification and neutralisation.. It also provides automatic navigation and helps minimise the operators load with its intuitive operator interface.. Norwegian Defence Materiel Agency project manager Dag Jarle Archer-Lure said: The Royal Norwegian Navy has with the Kongsberg Minesniper MkIII a state of the art One Shot Weapon System designed to meet the MCM fleets need for an effective countermine tool.. In addition, the system with its upgraded training vehicles provides the operators with a proven ...
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, erythromycin, ritonavir, cobicistat-containing products), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), ephedrine. May be antagonized by cholestyramine. May potentiate cyclosporine. May antagonize anticoagulants (monitor), isoniazid, other CYP3A4 substrates (eg, indinavir, erythromycin). Aminoglutethimide may diminish adrenal suppression by corticosteroids. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin or other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Toxic epidermal necrolysis possible with thalidomide. Concomitant indomethacin: may get false-negative on dexamethasone suppression test. May suppress reactions to skin tests.. ...
The presence of aromatase activity, estrogen receptors, and estrogenic responsiveness in MCF-7 human breast cancer cells has allowed this cell line to be used as a unique in vitro system for investigating the biological activities of potentially therapeutic aromatase inhibitors. We now report the results of studies which have examined the cytotoxicity, antiaromatase, and intrinsic estrogenic activities of aminoglutethimide, 1,2-dehydrotestolactone (testolactone), dihydrotestosterone, 4-hydroxy-4-androstene-3,17-dione, and 10-propargylestr-4-ene-3,17-dione within MCF-7 monolayer cultures. Cell viability was determined by trypan blue exclusion, and aromatase activity was assessed by quantifying the amounts of [3H]estradiol formed from [3]testosterone. Estrogenic activity was assessed by examining the ability of each inhibitor to increase cytoplasmic progesterone receptor and deplete cytoplasmic estrogen receptor concentrations in these cells during a 5-day incubation period. Cytoplasmic ...
The paper presents the results of the analysis of rates of cell cycle and fragmentation of DNA of rat adrenal cells in administration of 0,9 % NaCl solution, lactoprotein with sorbitol or HAES-LX-5%. No significant effect on the abovementioned rates in intact animals was noted throughout the observation (day 1, 3, 7, 14, 21 and 30).. ...
Compare los precios de hydrocortisone (anusol hc) 5 mg en farmacias en línea verificadas o en farmacias locales. Imprima cupones gratuitos para hydrocortisone, compre de manera segura y ahorre dinero en el costo de sus medicamentos hoy.
Gentaur molecular products has all kinds of products like :search , BioBasic \ Hydrocortisone \ HB0506 for more molecular products just contact us
Hydrocortisone in Punjabi - ਵਰਤੋਂ, ਖੁਰਾਕ, ਬੁਰੇ ਪ੍ਰਭਾਵ, ਲਾਭ, ਪਰਸਪਰ ਪ੍ਰਭਾਵ ਅਤੇ ਚੇਤਾਵਨੀ ਦੇਖੋ
Cultures of minced, whole-ovary (whole-ovary culture) were used to determine if three selected chemicals altered steroidogenic profiles. First, phenolsulfonthalein (PST), when used in culture medium, was tested for its influence on in vitro steroidogenesis. Next, aminoglutethimide (AGTP; 0 or 150 mg/kg once) and di(2-ethylhexyl)phthalate (DEHP; 0 or 1500 mg/kg/day for 10 days) were administered in vivo to young adult cycling rats, and the ovaries and adrenals were removed and cultured for 1 h. Ovarian steroidogenic profiles of progesterone (P), testosterone (T), and estradiol (E) release into the medium were measured using radioimmunoassay techniques. PST in medium significantly altered. Therefore, PST was excluded in the later studies. DEHP altered steroid profiles so that proestrus appeared to be delayed. AGTP decreased P and E production significantly, and T production was increased slightly in proestrus ovaries. These AGTP alterations in T and E resulted in a highly significant increase in ...
Aminoglutethimide (AG) 500 mg was administered orally to four normal volunteers and eight patients undergoing treatment for metastatic breast cancer. In each subject the acetylator phenotype was established from the monoacetyldapsone (MADDS)/dapsone (DDS) ratio. Acetylaminoglutethimide (acetylAG) rapidly appeared in the plasma and its disposition paralleled that of AG. A close relationship (P less than 0.01) was observed between the acetyl AG/AG and MADDS/DDS ratio suggesting that AG may undergo polymorphic acetylation like DDS. AG half-life was 19.5 +/- 7.7 h in seven fast acetylators of DDS and 12.6 +/- 2.3 h in five slow acetylators and its apparent metabolic clearance was significantly (P less than 0.01) related to the acetylAG/AG ratio. Over 48 h the fast acetylators excreted 7.7 +/- 4.4% of the administered AG dose in the urine as unchanged AG as compared to 12.4 +/- 2.8% in slow acetylators. A much smaller fraction of the dose was excreted as acetylAG: 3.6 +/- 1.5% by fast and 1.9 +/- ...
Principal Investigator:AKAKURA Koichiro, Project Period (FY):1997 - 1998, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Urology
AbstractObjective:This study aimed to evaluate self-reported cognitive functioning of postmenopausal breast cancer patients before and during endocrine treatment compared with healthy female controls, and to investigate associations between self-reported cognitive functioning, cognitive test perform
Jadit Hydrocortisone is mainly associated with symptoms and indications-The International Classification of Diseases (ICD)- R01AD60-Hydrocortisone, combinations ...
Question - My 11 month old daughter has been using Hydrocortisone 0.5% - E3. Find the answer to this and other Medical questions on JustAnswer
1997-2005 Healthboard.com. Healthboard.com is a purely informational website, and should not be used as a substitute for professional legal, medical or technical advice. ...
Representative and non-limiting examples for medicines, the according to this embodiment of the invention include antineoplastic agents such as vincristine, Vinblastine, vindesine, busulfan, chlorambucil, spiroplatin, cisplatin, Carboplatin, methotrexate, adriamycin, mitomycin, bleomycin, cytosine arabinoside, Arabinosyladenine, mercaptopurine, mitotane, procarbazine, dactinomycin (Antinomycin D), daunorubicin, doxorubicin hydrochloride, taxol, plicamycin, Aminoglutethimide, estramustine, flutamide, leuprolide, megestrol acetate, Tamoxifen, testolactone, trilostane, amsacrine (m-AMSA), asparaginase (L-asparaginase), etoposide, interferon a-2a and 2b, blood products like hematoporphyrins or Derivatives of the foregoing; biological reaction modifiers such as muramyl peptides; Antifungals such as ketoconazole, nystatin, griseofulvin, Flucytosine, miconazole or amphotericin B; Hormones or hormone analogues like growth hormone, the melanophore hormone, estradiol, beclo methasone dipropionate, ...
Three patients with primary aldosteronism due to adrenocortical carcinoma were studied, two with hyperaldosteronism alone and one also with hypercortisolism; in the later stages all three had hypersecretion of glucocorticoid and androgenic hormones. Although clinical presentations were similar to those of patients with benign adenoma, all had significantly higher concentrations of deoxycorticosterone and aldosterone and more profound hypokalemia. Stimulation with adrenocorticotropin in two patients showed a good cortisol response but no aldosterone response. The circadian rhythm for Cortisol was normal but absent for aldosterone and deoxycorticosterone. Sequential 24-hour circadian studies in one patient showed that as the disease progressed, corticosterone and finally Cortisol lost their circadian rhythms. Treatment with spironolactone, mitotane, or aminoglutethimide had transient clinical effects. The patients died 2 to 13 years later. ...
FOR SALE ! Sustanon sustenon deca durabolin nandrolone mix NE3 dianabol dbol anabol Androxon Testocap Testocaps naposim anadrol anapolon clomid durabol clomiphene citrate Gonadotropina HCG Human Chorionic Gonadotropin hGH Human Growth Hormone somatropin saizen jintropin hormotrop bergamo brazil nordictropin caffeine gensci Eutropin LG Life Science igtropin GHRH GRF GHRF orgabolin andriol icyplex testosterone undecanoate proviron norma deca cytadren PGCL Nebido Aminoglutethimidum Oxafort Maxigan Novartis Equigan Ultragan Oxandrovet Aminoglutethimide methandrostenlone Orimeten Percocet Endocet primobolan androlon methenolone acetate winstrol azolol stanozolol ILIUM cetabon Ampavit Stanosus Stanazolic Zambon Estano pets Metenol QV schering decabol stanabol stanol body research LA Pharma la anabolic Oxydrol stanoject bacteriostatic water nolvadex tamoxifen citrate Hubei Huangshi Nanshang Salbutol Albuterol Salbuterol Sulphate diazepam Arimidex anastrozole parabolan clenbuterol spiropent Suprimo ...
0147]In another specific embodiment, the methods of the invention encompass administration of a composition of the invention in combination with the administration of one or more prophylactic/therapeutic agents that are anti-cancer agents such as, but not limited to: acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, decarbazine, decitabine, dexormaplatin, dezaguanine, dezaguanine ...
0164] Additional examples of anti-cancer agents (e.g., chemotherapeutic) that can be used in conjunction with the presently disclosed subject matter, including pharmaceutical compositions and dosage forms and kits of the presently disclosed subject matter, include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; ...
Learn about the potential side effects of Hydrocortisone 1% In Absorbase (hydrocortisone). Includes common and rare side effects information for consumers and healthcare professionals.
Check out this diamond eternity ring in 18ct gold. Head over to bouf.com where youll also find some cool rings plus many more product & gift ideas.
Body mass index (BMI) affects the level of estradiol and estrone sulfate suppression achieved when treating postmenopausal women with estrogen receptor (ER)-positive breast cancer with either of two aromatase inhibitors, anastrozole or letrozole.
Alpha365 breaks down into a few components that create a trifecta that can reduce muscle breakdown, while targeting anabolic stimulation and estrogen suppression. It provides key nutrients that combat deficiencies that can possibly compromise the maximum amounts of testosterone that your body can produce.
I tend to get eczema and hydrocortisone cream is the only thing that works to relieve it. However, I have read that hydrocortisone can interfere with
Zymox Otic w/ Hydrocortisone 1.0% (1.25oz) and other products can be found to fulfill the needs of all your pets, our pets, at EntirelyPets. Free Shipping* on most items!
Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first. This drug should not be used with the following medication because very serious interactions may occur: febuxostat. If you are currently using the medication listed above, tell your doctor or pharmacist before starting theophylline. Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: adenosine, adrenaline-like drugs (e.g., ephedrine, phenylephrine, pseudoephedrine), allopurinol, aminoglutethimide, certain antiarrhythmic drugs (e.g., mexiletine, propafenone), anti-seizure drugs (e.g., carbamazepine, phenytoin, phenobarbital), benzodiazepines (e.g., diazepam, flurazepam), certain beta blockers (e.g., propranolol), birth control pills, cimetidine, digoxin, disulfiram, fluvoxamine, ...
Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first. This drug should not be used with the following medication because very serious interactions may occur: febuxostat. If you are currently using the medication listed above, tell your doctor or pharmacist before starting theophylline. Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: adenosine, adrenaline-like drugs (e.g., ephedrine, phenylephrine, pseudoephedrine), allopurinol, aminoglutethimide, certain antiarrhythmic drugs (e.g., mexiletine, propafenone), anti-seizure drugs (e.g., carbamazepine, phenytoin, phenobarbital), benzodiazepines (e.g., diazepam, flurazepam), certain beta blockers (e.g., propranolol), birth control pills, cimetidine, digoxin, disulfiram, fluvoxamine, ...
We conducted an exploratory phase II study to assess the efficacy of treatment with ketoconazole/hydrocortisone in combination with dutasteride in men with CRPC. The largest previous study of ketoconazole (Cancer and Leukemia Group B 9583) analyzed responses to ketoconazole/hydrocortisone given concurrently or subsequent to antiandrogen withdrawal (response rates of 27% and 32%, respectively), so the current study was powered to determine whether the response was ,32% (23). Although response rates to ketoconazole in other smaller studies have ranged from 20% to 75% (22), the 56% response rate to KHAD indicates that 5α-reductase inhibition by dutasteride may enhance the response rate to ketoconazole/hydrocortisone. In contrast to the response rate, response durations in this study were markedly longer than those reported previously for ketoconazole/hydrocortisone. The median duration of response was 20 months, and 9 of the 32 responding patients had not yet progressed at the time of this ...
Jangan lewatkan kesempatan untuk memiliki Lidocaine hcl - hydrocortisone acetate with an aloe topco associates llc hydrocortisone dengan harga murah hanya di website ini. Nevertheless, on the basis and of those data we arbitrarily added Sandoz anuzinc hc plus to the test solutions at a concentration field of 9 mg per ml to give inmates an effective hydrocortisone concentrati
Biocidan Hydrocortisone information about active ingredients, pharmaceutical forms and doses by Sanofi-Aventis, Biocidan Hydrocortisone indications, usages and related health products lists
WebMD provides important information about Hydrocortisone Topical such as if you can you take Hydrocortisone Topical when you are pregnant or nursing or If Hydrocortisone Topical dangerous for children or adults over 60.
Structure, properties, spectra, suppliers and links for: Hydrocortisone butyrate (JP15/USP), 13609-67-1, Hydrocortisone butyrate [USAN:BAN:JAN].
The agents used for endocrine therapy in patients with breast cancer have changed markedly over the past decade. Tamoxifen remains the anti-oestrogen of choice, but could be replaced by the oestrogen receptor down-regulator ICI 182780 or by the fixed ring triphenylethylene arzoxifene (previously SERM III) soon. Whilst aminoglutethimide and 4-OH androstenedione were the aromatase inhibitors of choice, they have been replaced by non-steroidal (anastrozole and letrozole) and steroidal (exemestane) inhibitors of high potency and low side effect profile. Previously, often used treatments such as progestogens (megestrol acetate and medroxyprogesterone acetate) and androgens are now rarely used or confined to fourth or fifth line treatments. The LHRH agonist, goserelin, remains the treatment of choice for pre-menopausal patients with advanced breast cancer although recent randomised trials indicate a response, time to progression and survival advantage for the combination of goserelin and tamoxifen ...
The aim of the study is to establish the short-term efficacy and safety of aromatase inhibition in restoring and maintaining eugonadism in hypogonadotrophic hypogonadal men. Secondary aim is to detect the short-term somatic and psychological effects.. Study design: Double blind randomized placebo-controlled trial.. Treatment: 26 weeks of either letrozole or placebo. All patients will start on 1 tablet per week, dose adjustments will be performed if serum testosterone or estradiol are outside the target range. All men will be prescribed a mildly hypocaloric diet.. Endpoints: BMI, body weight, waist circumference, body composition, exercise capacity, serum levels of several hormone markers, glucose tolerance, psychological characteristics.. All patients will be measured 6 times during the study. ...
Tumor Library - Cancer Oncology - Welcome to the James O. Johnston Orthopaedic Oncology Tumor Library. This site is intended to offer the oppotunity to cancer research of Orthopaedic Oncology diagnosis slides and imagery from Dr. Johnson s personal library.
Tumor Library - Cancer Oncology - Welcome to the James O. Johnston Orthopaedic Oncology Tumor Library. This site is intended to offer the oppotunity to cancer research of Orthopaedic Oncology diagnosis slides and imagery from Dr. Johnson s personal library.
Learn about the potential side effects of hydrocortisone/urea topical. Includes common and rare side effects information for consumers and healthcare professionals.
Hydrocortisone ointment is considered as a safe steroid to use that is readily available over-the-counter or a stronger version can be prescribed by a doctor.
গুণ Lyophilized পাউডার ইনজেকশন নির্মাতারা & রপ্তানিকারক - কেনা ইনজেকশন, Hydrocortisone সোডিয়াম Succinate জন্য ইনজেকশন 100mg জন্য হাইড্রোকোরিসিসন পাউডার চীন থেকে উত্পাদক.
... is the generic name of the drug and its INN, USAN, and BAN, while aminoglutéthimide is its DCF and ... Aminoglutethimide (AG), sold under the brand names Elipten, Cytadren, and Orimeten among others, is a medication which has been ... ISBN 978-1-56363-429-1. Siraki AG, Bonini MG, Jiang J, Ehrenshaft M, Mason RP (July 2007). "Aminoglutethimide-induced protein ...
Cash, Ralph; Brough, A. Joseph; Margo, N.P.Cohen; Satoh, Paul S. (1967). "Aminoglutethimide as an inhibitor of adrenal ... Cohen, Margo P. (1968). "Aminoglutethimide inhibition of adrenal desmolase activity". Proc Soc Exp Biol Med. 127 (4): 1086-1090 ...
Aminoglutethimide Piperidione Methyprylone Pyrithyldione Barceloux DG (2012). Medical Toxicology of Drug Abuse: Synthesized ...
Piperidinediones inclide Glutethimide, Methyprylon, Pyrithyldione, Glutarimide, and Aminoglutethimide. The first 3, ( ...
Aminoglutethimide has an oral administration and a usual dosage range between 250 and 100 mg/day. The drug has good oral ... Aminoglutethimide is an NSAIs and therefore inhibits aromatase among other biosynthesis and is for example used to treat ... Aminoglutethimide has a good distribution around the body and is partly metabolized in the liver by acetylation. The ... In 1960 aminoglutethimide was marketed as an anticonvulsant. Later in 1963, a doctor at the Sinai Hospital in Detroit ...
These drugs include aminoglutethimide, ketoconazole, and abiraterone acetate. Aminoglutethimide inhibits cholesterol side-chain ... The earlier androgen synthesis inhibitors aminoglutethimide and ketoconazole have only limitedly been used in the treatment of ... The androgen synthesis inhibitors aminoglutethimide and ketoconazole were first marketed in 1960 and 1977, respectively, and ... These include, to varying extents, cyproterone acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, and ...
Analogues of mitotane include aminoglutethimide, amphenone B, and metyrapone. Mitotane was introduced in 1960 for the treatment ...
The aromatase inhibitor aminoglutethimide induces the metabolism of tamoxifen. Conversely, the aromatase inhibitor letrozole ...
Analogues of metyrapone include aminoglutethimide, amphenone B, and mitotane. Metyrapone has been found in early human trials ...
... inhibitors include aminoglutethimide, ketoconazole, and mitotane, among others. ...
... aminoglutethimide, and sulfamethazine. NAT2 is involved in the metabolism of xenobiotics, which can lead to both the ...
Ketoconazole can cause liver damage with prolonged use, and aminoglutethimide can cause skin rashes. When hormonal treatment is ... Medications that block the production of adrenal androgens such as DHEA include ketoconazole and aminoglutethimide. Because the ...
This makes it potentially useful in the treatment of breast cancer, and with fewer side effects than aminoglutethimide, but its ... MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M (October 1992). "The influence of aminoglutethimide and its ... but instead has pharmacological activity as a selective aromatase inhibitor similar to the related drug aminoglutethimide and ...
Aminoglutethimide inhibits both aromatase and other enzymes critical for steroid hormone synthesis in the adrenal glands. It ...
Other steroidogenesis inhibitors besides ketoconazole and levoketoconazole include the nonsteroidal compound aminoglutethimide ...
... and aminoglutethimide. They are used to treat Cushing's syndrome. Antiglucocorticoids could be effective antidepressants for a ...
... s (AIs) include: Aminoglutethimide (Elipten, Cytadren, Orimeten) Testolactone (Teslac) Anastrozole (Arimidex ...
The combination of MPA with aminoglutethimide to treat metastases from breast cancer has been associated with an increase in ...
Abiraterone acetate Ketoconazole Seviteronel Aminoglutethimide Alfatradiol Dutasteride Epristeride Finasteride Saw palmetto ...
In the past, surgical adrenalectomy and early androgen biosynthesis inhibitors like ketoconazole and aminoglutethimide were ... However, adrenalectomy is an invasive procedure with high morbidity, ketoconazole and aminoglutethimide have relatively high ...
... aminoglutethimide, exemestane, formestane, and testolactone are banned. Selective estrogen receptor modulators, including ...
Cholesterol side-chain cleavage enzyme (P450scc, CYP11A1) inhibitors such as aminoglutethimide, ketoconazole, and mitotane ... Aromatase inhibitors (AIs) such as aminoglutethimide, anastrozole, exemestane, letrozole, and testolactone inhibit the ...
... proven with the blockade of aminoglutethimide (AG, known to block P450-mediated enzymes. Harry Brodie, a chemist, joined the ...
List of corticosteroids List of corticosteroid cyclic ketals List of corticosteroid esters Aminoglutethimide blocks ...
... and aminoglutethimide, have corticotropic or procorticotropic effects. Anticorticotropins are analogous to antigonadotropins ...
... aminoglutethimide MeSH D03.383.621.808.800 - thalidomide MeSH D03.383.621.808.930 - triacetoneamine-n-oxyl MeSH D03.383.621.815 ...
... aminoglutethimide, fadrozole, finrozole, letrozole, liarozole, norendoxifen, rogletimide (pyridoglutethimide), vorozole Other ... steroidogenesis inhibitors: aminoglutethimide, ketoconazole, orteronel, seviteronel, others Miscellaneous: tanaproget ( ...
Aminoglutethimide (3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione), which was originally introduced as an anticonvulsant in 1960 ...
They include: Antiglucocorticoids - e.g., mifepristone, ketoconazole, aminoglutethimide Antimineralocorticoids - e.g., ...
Inhibitors of cholesterol side-chain cleavage enzyme (P450scc), such as aminoglutethimide and ketoconazole, may block ...
Aminoglutethimide is an effective endocrine therapy in advanced postmenopausal breast cancer, particularly for bone deposits. ... Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and ... Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Harris AL., Powles TJ., Smith IE., Coombes RC., ... Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and ...
Aminoglutethimide is an adrenal steroid inhibitor, prescribed for Cushing syndrome.. * Aminohippurate Sodium ...
Exfoliative dermatitis (ED) is a definitive term that refers to a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Exfoliative dermatitis is characterized by erythema and scaling involving the skins surface and often obscures the primary lesions that are important clues to understanding the evolution of the dis...
First-generation: Aminoglutethimide. *Testolactone. *Second-generation: Fadrozole. *Formestane. *Third-generation: Anastrozole ...
Cocconi G, Bisagni G, Ceci G, et al.: Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line ... An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73 (2): 354-61, 1994. [ ...
Be sure to mention aminoglutethimide (Cytadren). Your doctor may need to change the doses of your medications or monitor you ...
Detailed drug Information for Truxophyllin. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. ...
When aminoglutethimide is used at the conventional daily dose of 1000 mg in combination with 40 mg of hydrocortisone these ... In the current study it was found that with twice daily treatment at the low dose of 125 mg aminoglutethimide plus 20 mg ... Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of ... Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ...
Aminoglutethimide. *Anastrozole. *Androsta-1,4,6-triene-3,17-dione (androstatrienedione). *Androsta-3,5-diene-7,17-dione ( ...
Are you familiar with essential information regarding the presentation of hypothyroidism, as well as best practices for diagnosis and treatment? Test your clinical knowledge with this short quiz.
AMINOGLUTETHIMIDE. AMINOPTERIN AND ITS SALTS. 4-AMINO-PTEROYL ASPARTIC ACID. AND ITS SALTS. AMINOPYRINE AND ITS DERIVATIVES. ...
... with aromatase inhibitory action 10 times more potent than the first generation aromatase inhibitor aminoglutethimide (Cytadren ...
Aminoglutethimide - Taken because the drug possesses the ability to inhibit the conversion of androgens to estrogens via the ...
Aminoglutethimide. The metabolism of Retapamulin can be increased when combined with Aminoglutethimide. ...
Aminoglutethimide (Cytadren). *Amphotericin B (Amphocin, Fungizone Intravenous). *Cholesterol-lowering drugs. *Anticoagulants ...
ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.
Aminoglutethimide - 125-84-8 - Toxicity: developmental. *Aminoglycosides - Toxicity: developmental. *1-Amino-2- ...
... anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; ...
aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; ... such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate, exemestane, formestane, fadrozole, vorozole, ...
Be sure to mention the medications listed in the IMPORTANT WARNING section and aminoglutethimide (Cytadren). Your doctor may ...
aminoglutethimide (used for some types of cancer). *ketoconazole (used to treat fungal infections) ...
Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine, aminoglutethimide. May ...
Effects of ACTH and aminoglutethimide administration on the morphological and functional responses of rat adrenal zona ...
Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. *Concomitant with potassium-depleting ...
Aminoglutethimide (AG) was the first AI to be developed for clinical use [34-36] and showed benefit initially in advanced ... Smith IE, Fitzharris BM, McKinna JA, Fahmy DR, Nash AG, Neville AM, Gazet JC, Ford HT, Powles TJ: Aminoglutethimide in ... Lipton A, Santen RJ: Proceedings: medical adrenalectomy using Aminoglutethimide and Dexamethasone in advanced breast cancer. ... Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol. 1992, 10 ...
  • Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. (ox.ac.uk)
  • Aminoglutethimide is an effective endocrine therapy in advanced postmenopausal breast cancer, particularly for bone deposits. (ox.ac.uk)
  • Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. (ox.ac.uk)
  • Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone. (ox.ac.uk)
  • When aminoglutethimide is used at the conventional daily dose of 1000 mg in combination with 40 mg of hydrocortisone these effects can result in clinically significant hypothyroidism and increases in the serum levels of oestrone in response to stimulation of adrenocorticotropic hormone (ACTH). (ox.ac.uk)
  • In the current study it was found that with twice daily treatment at the low dose of 125 mg aminoglutethimide plus 20 mg hydrocortisone there was no significant increase in oestrone levels after ACTH stimulation. (ox.ac.uk)
  • Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. (drugpatentwatch.com)
  • PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer. (drugpatentwatch.com)
  • Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. (drugpatentwatch.com)
  • Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase. (ox.ac.uk)
  • Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais. (napra.ca)
  • Multicomponent Materials to Improve Solubility: Eutectics of Drug Aminoglutethimide. (mpg.de)
  • The goal is to inhibit the enzymes responsible for cortisol synthesis with adrenal enzyme inhibitors, such as metyrapone, aminoglutethimide, and ketoconazole. (medscape.com)
  • These drugs include ketoconazole, aminoglutethimide, metyrapone, mitotane, and etomidate, and they exert their effect by inhibition of steroidogenic enzymes such as 11β-hydroxylase and 17α-hydroxylase. (scitechnol.com)
  • Ketoconazole, aminoglutethimide, and abiraterone acetate (Zytiga) are three androgen synthesis inhibitors that are approved in the United States. (arizonaoncology.com)
  • The failure of aminoglutethimide to lower ASD levels and drug toxicity as a result of high aminoglutethimide levels are two factors that lead clinicians from aminoglutethimide to ketoconazole for adrenal androgen synthesis blockade [ 15 ]. (ijbs.com)
  • Aminoglutethimide has been used but it has greater toxicity than ketoconazole but similar response rates. (cancerstreatment.com)
  • Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. (nih.gov)
  • Aminoglutethimide depleted dehydroepiandrosterone-sulfate (DHEA-sulfate), levels and androstenedione (ASD) levels remained unchanged [ 15 ]. (ijbs.com)
  • Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. (ox.ac.uk)
  • 6. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. (nih.gov)
  • 15. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. (nih.gov)
  • One in vitro study [4] even noted that chysin is similar in potency and effectiveness to aminoglutethimide, a pharmaceutical aromatase inhibitor used clinically in cases of estrogen-dependent carcinoma. (nutrientjournal.com)
  • Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer. (ox.ac.uk)
  • Reduced gradually on the advice of the doctor in charge the symptoms that come along with low testosterone this means that without the administration of aromatase inhibitors such as Anastrozole or Aminoglutethimide, estrogenic effects will appear over time in men. (animeconji.org)
  • Anastrozole was found to be 200 times more potent than aminoglutethimide and was more than three times more effective than formestane. (stuggigaming.de)
  • Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. (ox.ac.uk)
  • 16. Aminoglutethimide--a new endocrine therapy in breast cancer. (nih.gov)
  • Aminoglutethimide-oral is used to stop the adrenal gland from making too much cortisol and other hormones. (alternativemedicals.com)
  • Aminoglutethimide is used to treat Cushing's syndrome, a disease that occurs when the body produces too much cortisol and other hormones. (alternativemedicals.com)
  • Metyrapone and aminoglutethimide have been the standard therapy, and, when the 2 agents are used in combination, adverse effects may be decreased. (medscape.com)
  • 4. Adrenal suppression with aminoglutethimide. (nih.gov)
  • Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. (clinicaladvisor.com)
  • 2. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. (nih.gov)
  • Synonyms of aminoglutethimide best drugs to get lean cases our understanding of these effects remains limited. (akrobotics.com)
  • Controlling symptoms of enhanced cytotoxic drugs and rosuvastatin were used to be diagnosed with aminoglutethimide: bvz003. (holabar.com)
  • Riboflavin is included with other drugs Femara to aminoglutethimide, and with poise, clots after heart surface. (lariberabilbao.com)
  • Aminoglutethimide is as effective at 125 mg twice a day without HC in its suppression of oestrogen levels as at 500 mg twice a day with HC, and its use in this form warrants clinical evaluation. (ox.ac.uk)
  • Consistent with this hypothesis, similar effects on adrenal mitochondrial cholesterol were produced by in vivo administration of the cholesterol side-chain cleavage inhibitor, aminoglutethimide, to ACTH-stimulated rats. (nih.gov)
  • 17. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer. (nih.gov)
  • That their steroid counterpart from last glaucoma surgery to infection onset, intraocular aminoglutethimide enhance the metabolism of corticosteroids and its therapeutic effects may be reduced. (floridacleanwaternetwork.org)
  • Treatment with aminoglutethimide of only four premenopausal breast cancer patients has been reported in which two patients responded. (ox.ac.uk)
  • 19. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. (nih.gov)
  • Resumen en inglés Using endothelium-denuded rat aortic rings incubated in Ca2+-free solution, we assessed the ability of testosterone to influence the contractile effect of phenylephrine, and the increase in resting tone (IRT) associated with Ca2+ ability to cross the plasma membrane. (worldwidescience.org)
  • 18. Resistance of the ovary to blockade of aromatization with aminoglutethimide. (nih.gov)
  • Resumen en inglés Purpose: To study the effects of mitomycin-C (MMC) on the corneal endothelium after pterygium surgery. (worldwidescience.org)
  • Various products instructions are valuable to me and effects in addition to muscle buy and with aminoglutethimide. (phldnc.com)
  • 8. Basic studies on aminoglutethimide. (nih.gov)
  • Resumen en inglés ABSTRACT Influence of long-term palm and corn oil diet supplement administration on rabbit aortic rings vasoconstriction and vasodilatation. (worldwidescience.org)